If MYMAN has listened to his first instinct and got into VRMLQ he would driving home with these ladies instead of just lookin' at this damn photo.MYMAN considered buyin' VRMLQ a few months ago but thought about it too much and stayed away because of concerns about Vermillion's financial health. VRMLQ is currently trading at $13.50 and it pains MYMAN to even think about this.
So what's the lesson here, my man? You gotta be willin' to take the risks, my man. OK, so what's next? Sometimes you can think much and you should just go by instinct.
What's a future VRMLQ? Maybe these are some candidates:
BIOMAGNETICS DIAGNOS (BMGP) 0.17
Biovest International, Inc. (BVTI) 0.45
Cell Robotics International Inc. (CRII) 0.0035
Imaging Diagnostic Systems, Inc. (IMDS) 0.0090
Longport, Inc. (LPTI) 0.0100
Wellstar International, Inc. (WLSI) 0.0002
You can think of anyone else, feel free to share, my man.
So what's the lesson here, my man? You gotta be willin' to take the risks, my man. OK, so what's next? Sometimes you can think much and you should just go by instinct.
What's a future VRMLQ? Maybe these are some candidates:
BIOMAGNETICS DIAGNOS (BMGP) 0.17
Biovest International, Inc. (BVTI) 0.45
Cell Robotics International Inc. (CRII) 0.0035
Imaging Diagnostic Systems, Inc. (IMDS) 0.0090
Longport, Inc. (LPTI) 0.0100
Wellstar International, Inc. (WLSI) 0.0002
You can think of anyone else, feel free to share, my man.
Next time my man... next time
ReplyDeleteour patience with HTDS will be well rewarded my man.
we have a proof that things can happen really fast. I really imagine that HTDS can go to 0.50$
2.5 billion mkt cap , its possible
God I hope so!
ReplyDeletePWRM--Power3 Medical Products, Inc. (Power3) is primarily engaged in
ReplyDeletecommercializing its intellectual properties in the area of diagnosis
and treatment of breast cancer, Amyotrophic Lateral Sclerosis (ALS),
Alzheimer’s disease and Parkinson’s disease. In the area of
neurodegenerative diseases and breast cancer, Power3 has completed
research and clinical validation studies involving over 1,500 patient
samples. Power3 uses biostatistical analysis to monitor appropriate
panels of biomarkers for diagnostic sensitivity and specificity for
disease, normal and disease controls. By testing patient body fluids
and tissues, including blood serum (for breast cancer and
neurodegenerative diseases), and bone marrow aspirates (for leukemia
patients), the Company has discovered protein biomarker patterns in
over 1,500 patient samples that cover a range of diseases.
Power3 expects to complete phase II clinical
validation trials of its blood serum diagnostics for Alzheimer's
disease (AD-NuroPro) in 2009, which will be followed by a filing with the
FDA.
1yr Target Est: $3.14
http://finance.yahoo.com/q?s=PWRM.OB
http://quotes.nasdaq.com/asp/Summ...
Power3 Medical Products:
http://www.onemedplace.com/database/list/cid/660/
Files for 3 Patents On Blood Test for Diagnosis Early Stage Breast Cancer
http://money.cnn.com/news/newsfeeds/articles/globenewswire/171789.htm
Files for Patent on Diagnosis of Early Stage Parkinsons Disease
http://www.tradingmarkets.com/.site/news/Stock%20News/2455943/
Positive Breakthrough for NuroPro(R) Blood Test for Alzheimer's
http://www.tradingmarkets.com/.site/news/Stock%20News/2349054/
Early Alzheimer's Diagnosis Offers Large Social, Fiscal Benefits
http://www.interestalert.com/story/08140002aaa064c0.nw/pkreysa/HELTHSCI/health/science.html
List of Acceptable U.S. Industries
http://www.fda.gov/AboutFDA/WorkingatFDA/Ethics/ucm079726.htm
Pinksheet:
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=pwrm
Pink sheet/otc Watchlist:
http://theotcinvestor.com/pre-market-otc-bb-and-pink-sheet-watchlist-...
Power3 Medical `On-Track and On-Plan` to Commercialize Diagnostic BloodTests
http://www.reuters.com/article/pressRelease/idUS163335+18-Mar-2009+BW...
Old news:
http://www.cohenresearch.com/reports/pwrm_update_09-24-07.pdf
Investors:
http://www.mffais.com/pwrm.ob
Technical Trading Overview:
http://news.tradingcharts.com/futures/5/9/128334095.html
You forgot PWRM, I am serious on this one.